Market Cap 614.36B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.43
Forward PE 21.76
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 6,930,219
Avg Vol 8,416,610
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 29%
Beta 0.24
Analysts Strong Sell
Price Target $274.08

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
justiceforb_85
justiceforb_85 Aug. 6 at 10:33 PM
$NBTX very under-the-radar. But good data for NBTXR3 in HNSCC/NSCLC and a prime BO candidate for $JNJ.
0 · Reply
atreus57
atreus57 Aug. 6 at 5:29 PM
$RNXT is a rare ~$50M biotech/medtech with BOTH real commercial revenue and a pivotal oncology catalyst. Q1 RenovoCath revenue: $563K, +136% QoQ. Active cancer centers grew from 5 at the start of 2025 to 16 by May, with 32 more in evaluation/onboarding. Cash: $12.4M; runway guided into H2 2027. TIGeR-PaC is randomized Phase III in locally advanced pancreatic cancer: 106 patients randomized, 74/86 required OS events, and the IDMC recommended continuing. Final data expected in 2027. $5-$6 implies roughly a $225M-$270M basic market cap. Plausible only if RNXT proves repeat orders, completes enrollment, scales centers/revenue and delivers a meaningful OS benefit. Warrants/dilution are the main risks. Not comparing size, but the rerating mechanics are familiar to investors in $LXRX $BMY $JNJ $MDT: platform validation + commercial traction + pivotal success. Bull path: $1.25-$1.50 on execution, 2+ on acceleration, $5-$6 on validated-platform status. #biotech #oncology
0 · Reply
TraderDaKing
TraderDaKing Aug. 6 at 4:49 PM
$ELTP $PFE $JNJ $MRNA $LLY Who is doing a deal with Elite?? SequestOx (ELI-200) is an investigational, abuse-deterrent opioid product developed by Elite Pharmaceuticals containing a combination of oxycodone hydrochloride and sequestered naltrexone for managing moderate to severe pain. How SequestOx WorksNormal Use: Taken orally as intended, the opioid agonist (oxycodone) releases for pain relief while the antagonist (naltrexone) stays locked inside and passes through the body unreleased.Tampering: If the capsule or beads are crushed, chewed, or dissolved, the naltrexone releases.Blockade: The released naltrexone blocks the euphoric high of oxycodone by binding to brain receptors, which deters recreational abuse. https://elitepharma.com/ Roaring Kitty?
0 · Reply
HydrogenH2
HydrogenH2 Aug. 6 at 4:13 PM
$JNJ I'm adding few shares !!
0 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 6 at 3:43 PM
$SLS Small, Important Details 👀 $SLS Tom Cavanaugh was just named Executive Vice President and Worldwide President of $JNJ 's Innovative Medicine Division. Who sits on the $SLS Board of Directors? Katherine Bach Kalin. Both served for years as senior executives in global strategy and product development, from 2012 to 2017? At CELGENE. Celgene: Both Tom and Katherine held senior leadership roles in global strategy/product development (2012-2017). $JNJ : Katherine spent nearly a decade at J&J in leadership/business development roles (2002-2011).
1 · Reply
parcha
parcha Aug. 6 at 3:18 PM
Jim Cramer's top 10 things to watch in the stock market Thursday $LLY $JNJ $MRK $ABBV Bunch of price target hikes for Eli Lilly after another beat-and-raise quarter yesterday. Morgan Stanley, BMO and Wells Fargo all raised. So did Leerink, which touted Lilly’s improving profitability and next-generation obesity drugs. Retatrutide is the one I’m most interested in. Lilly is still my No. 1 pharma stock, followed by fellow Club name Johnson & Johnson. I also like Abbvie and Merck. https://www.cnbc.com/2026/08/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
Tnitty4371
Tnitty4371 Aug. 6 at 3:12 PM
$EZRA 🎁💎🎁💵🎁💎 $TSLA $SPY $JNJ $AZI
0 · Reply
Wallstfan
Wallstfan Aug. 6 at 2:17 PM
$JNJ $8 swing today wow!
0 · Reply
StockTraderLog
StockTraderLog Aug. 6 at 1:38 PM
$TSLA $SKHY $JNJ $MSFT Take my profit at the open. Not bad for starting the day. Win some and loss some.
0 · Reply
BarkingPuppy
BarkingPuppy Aug. 6 at 1:22 PM
$ELTP $JNJ $DJT $GME Coming to TRUMPRX Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL Elite is partnered with Space-X. Roaring Kitty endorsed.
0 · Reply
Latest News on JNJ
Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 3 days ago

Johnson & Johnson Transcript: Investor update


Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 4 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device


Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 8 days ago

Johnson & Johnson lowers 2026 profit forecast


Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 8 days ago

Explainer: Can J&J finally put the talc litigation behind it?


Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 9 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits


J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 9 days ago

J&J offers $5.5bn to settle baby powder lawsuits


DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 21 days ago

DePuy Synthes Acquires Expanding Innovations™


Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 22 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 22 days ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 22 days ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 22 days ago

Johnson & Johnson Quarterly report: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 22 days ago

Johnson & Johnson Hikes Guidance, Stock Falls


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 22 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise


Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 22 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 4 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 2 months ago

Johnson & Johnson to buy Firefly Bio for $1 billion


justiceforb_85
justiceforb_85 Aug. 6 at 10:33 PM
$NBTX very under-the-radar. But good data for NBTXR3 in HNSCC/NSCLC and a prime BO candidate for $JNJ.
0 · Reply
atreus57
atreus57 Aug. 6 at 5:29 PM
$RNXT is a rare ~$50M biotech/medtech with BOTH real commercial revenue and a pivotal oncology catalyst. Q1 RenovoCath revenue: $563K, +136% QoQ. Active cancer centers grew from 5 at the start of 2025 to 16 by May, with 32 more in evaluation/onboarding. Cash: $12.4M; runway guided into H2 2027. TIGeR-PaC is randomized Phase III in locally advanced pancreatic cancer: 106 patients randomized, 74/86 required OS events, and the IDMC recommended continuing. Final data expected in 2027. $5-$6 implies roughly a $225M-$270M basic market cap. Plausible only if RNXT proves repeat orders, completes enrollment, scales centers/revenue and delivers a meaningful OS benefit. Warrants/dilution are the main risks. Not comparing size, but the rerating mechanics are familiar to investors in $LXRX $BMY $JNJ $MDT: platform validation + commercial traction + pivotal success. Bull path: $1.25-$1.50 on execution, 2+ on acceleration, $5-$6 on validated-platform status. #biotech #oncology
0 · Reply
TraderDaKing
TraderDaKing Aug. 6 at 4:49 PM
$ELTP $PFE $JNJ $MRNA $LLY Who is doing a deal with Elite?? SequestOx (ELI-200) is an investigational, abuse-deterrent opioid product developed by Elite Pharmaceuticals containing a combination of oxycodone hydrochloride and sequestered naltrexone for managing moderate to severe pain. How SequestOx WorksNormal Use: Taken orally as intended, the opioid agonist (oxycodone) releases for pain relief while the antagonist (naltrexone) stays locked inside and passes through the body unreleased.Tampering: If the capsule or beads are crushed, chewed, or dissolved, the naltrexone releases.Blockade: The released naltrexone blocks the euphoric high of oxycodone by binding to brain receptors, which deters recreational abuse. https://elitepharma.com/ Roaring Kitty?
0 · Reply
HydrogenH2
HydrogenH2 Aug. 6 at 4:13 PM
$JNJ I'm adding few shares !!
0 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 6 at 3:43 PM
$SLS Small, Important Details 👀 $SLS Tom Cavanaugh was just named Executive Vice President and Worldwide President of $JNJ 's Innovative Medicine Division. Who sits on the $SLS Board of Directors? Katherine Bach Kalin. Both served for years as senior executives in global strategy and product development, from 2012 to 2017? At CELGENE. Celgene: Both Tom and Katherine held senior leadership roles in global strategy/product development (2012-2017). $JNJ : Katherine spent nearly a decade at J&J in leadership/business development roles (2002-2011).
1 · Reply
parcha
parcha Aug. 6 at 3:18 PM
Jim Cramer's top 10 things to watch in the stock market Thursday $LLY $JNJ $MRK $ABBV Bunch of price target hikes for Eli Lilly after another beat-and-raise quarter yesterday. Morgan Stanley, BMO and Wells Fargo all raised. So did Leerink, which touted Lilly’s improving profitability and next-generation obesity drugs. Retatrutide is the one I’m most interested in. Lilly is still my No. 1 pharma stock, followed by fellow Club name Johnson & Johnson. I also like Abbvie and Merck. https://www.cnbc.com/2026/08/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
Tnitty4371
Tnitty4371 Aug. 6 at 3:12 PM
$EZRA 🎁💎🎁💵🎁💎 $TSLA $SPY $JNJ $AZI
0 · Reply
Wallstfan
Wallstfan Aug. 6 at 2:17 PM
$JNJ $8 swing today wow!
0 · Reply
StockTraderLog
StockTraderLog Aug. 6 at 1:38 PM
$TSLA $SKHY $JNJ $MSFT Take my profit at the open. Not bad for starting the day. Win some and loss some.
0 · Reply
BarkingPuppy
BarkingPuppy Aug. 6 at 1:22 PM
$ELTP $JNJ $DJT $GME Coming to TRUMPRX Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL Elite is partnered with Space-X. Roaring Kitty endorsed.
0 · Reply
HydrogenH2
HydrogenH2 Aug. 6 at 1:03 PM
$JNJ $251... $260... rinse & repeat ??
0 · Reply
StockTraderLog
StockTraderLog Aug. 6 at 2:17 AM
$JNJ YOLO CALL. I was up 3.5K intraday, and flips -3.6K. I hopium for 260 by few days...
0 · Reply
LiveTradePro
LiveTradePro Aug. 6 at 1:51 AM
$JNJ This stock just keeps talking to me; and why I added on the dip yesterday and added one more time today Would not be surprised to see this go to test near, or at the all time high. Maybe higher https://share.trendspider.com/chart/JNJ/6682guyos4
0 · Reply
wyoming2020
wyoming2020 Aug. 5 at 11:29 PM
$VKTX I'd be thrilled with an all share by strong player that needs metabolic, like a $GSK or $JNJ or even $BAYRY. I love how Glaxo has rebuilt Oncology and HIV, would be very cool to bring in Viking. Let's not get too excited until summer over. Summer is about rest and doldrums. People never make good decisions when too hot and miserable. September, Q4 much better time.
0 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 5 at 11:10 PM
$SLS Part 3. No Open Market purchases after J.P Morgan 1x1 meetings with $JNJ and $PFE . Cluster purchases came before J.P Morgan 1x1 because all insiders and independent BOD have MNPI. Negotiations have been going on under strict NDA/MOU since December 2025. Now you all understand why we voted 3 million shares in favor of Dr. Stergiou stock award. We want Dr. Stergiou aligned with Comon Retail folks here that have been longs for a very long time. Dr. Stergiou has 1,875,000 reasons to Negotiate the best BO! ✌️🙏❤️‍🩹
2 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 5 at 11:09 PM
$SLS part 2 Katrina Helle @KatrinaHelle $PFE.X $SLS Part 2. Katherine Bach is A deep immunotherapy expert. Previously at Celgene (sold to BMS for $74 BILLION) Experienced in AML, hematology, cell therapies Very familiar with survival data patterns & regulatory signals. Katherine Kalin's stock purchase is especially bullish because she's not just any board member, she led M&A strategy at Celgene and BOD at $JNJ .
1 · Reply
Pearl_Power
Pearl_Power Aug. 5 at 6:44 PM
$JNJ higher low off pivot? DCB looks different. Upside limited but tradeable
0 · Reply
Quantumup
Quantumup Aug. 5 at 6:35 PM
Oppenheimer reiterated $CMPS Outperform-$20/said We view CMPS's 2Q26 update as reinforcing our conviction in COMP360 (psilocybin), while $433M cash provides expected runway into 2028 beyond potential launch. ATAI - $LLY STIM $JNJ GHRS HELP DFTX Oppenheimer added—CMPS represents a leader in psychedelics with COMP360 potentially becoming the first-ever FDA-approved psychedelic therapy in 1H27, and currently expects NDA completion in 4Q26 that features two positive Ph3 trials in >1K patients. Management emphasized progress with the FDA rolling review, commercial readiness initiatives, payor engagement, and salesforce buildout ahead of launch. We believe the Ph3 COMP006 durability data support ~3-4x annual dosing that enables favorable economics for clinics and payors. Meanwhile, we see increasing focus on additional COMP360 opportunities beyond TRD including PTSD and other adjacent neuropsychiatric indications. Our recent KOL discussion supports our confidence. We update our model with actuals.
0 · Reply
Wallstfan
Wallstfan Aug. 5 at 5:34 PM
0 · Reply
TraderDaKing
TraderDaKing Aug. 5 at 5:26 PM
$ELTP $MRNA $JNJ $PFE Nice new product added to our Company. Good Job Elite Family. Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's disease. This product is marketed and sold under the Elite Laboratories, Inc. label.
0 · Reply
StockTraderLog
StockTraderLog Aug. 5 at 5:15 PM
$JNJ YOLO 2DTE CALL. Wish me luck 🙏 😅
0 · Reply
TraderDaKing
TraderDaKing Aug. 5 at 4:53 PM
$JNJ $LLY So who is doing a deal With Elite??????
0 · Reply